Improving Targeted Therapeutics in NSCLC Management
Before closing out his discussion on NSCLC, Sandip Patel, MD, shares his excitement for evolving targeted strategies and improved patient outcomes.
EGFR-Targeted Therapy in NSCLC: Optimizing Sequencing and Combinations
Focusing on the broader treatment armamentarium for EGFR-mutated NSCLC, Sandip Patel, MD, considers possible sequencing and combination strategies.
Targeting Rare EGFR Mutations in NSCLC: Afatinib and Mobocertinib
Sandip Patel, MD, highlights the use of afatinib and mobocertinib, respectively, to treat NSCLC with rare EGFR-mutation variants.
Overview of EGFR-Mutated Non–Small Cell Lung Cancer
Insight on EGFR-mutated non–small cell lung cancer’s impact on treatment options and overall patient prognoses.
Optimal Molecular Testing Strategies in Non–Small Cell Lung Cancer
Expert perspectives on the current landscape of molecular profiling in patients with non–small cell lung cancer.
A Novel Combination Immunotherapy Approach for Neuroendocrine Tumors
ONCOLOGY recently spoke with Dr. Sandip Patel about a potential novel therapeutic ap- proach to treating patients with neuroendocrine tumors.
2 Clarke Drive Cranbury, NJ 08512